Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

CORZ Investors Have Opportunity to Lead Core Scientific, Inc. Securities Fraud Lawsuit

1:00 pm ET December 7, 2022 (PR Newswire) Print

Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Core Scientific Inc. ("Core Scientific" or the "Company") (NASDAQ: CORZ).

https://mma.prnewswire.com/media/1219482/Glancy_Prongay_and_Murray_LLP.jpg

Class Period: January 3, 2022 - October 26, 2022Lead Plaintiff Deadline: January 13, 2023

If you wish to serve as lead plaintiff of the Core Scientific lawsuit, you can submit your contact information at www.glancylaw.com/cases/core-scientific-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors: (1) that, due in part to the expiration of a favorable pricing agreement, the Company was experiencing increasing power costs; (2) that the Company's largest customer, Gryphon, lacked the financial resources to purchase the necessary miner rigs for Core Scientific to host; (3) that the Company was not providing hosting services to Celsius as required by their contract; (4) that the Company had implemented an improper surcharge to pass through power costs to Celsius; (5) that, as a result of the foregoing alleged breaches of contract, the Company was reasonably likely to incur liability to defend itself against Celsius; (6) that, as a result of the foregoing, the Company's profitability would be adversely impacted; (7) that, as a result, there was likely substantial doubt as to the Company's ability to continue as a going concern; and (8) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish tolearn moreabout this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

https://c212.net/c/img/favicon.png?sn=LA58278&sd=2022-12-07

View original content to download multimedia:https://www.prnewswire.com/news-releases/corz-investors-have-opportunity-to-lead-core-scientific-inc-securities-fraud-lawsuit-301696660.html

SOURCE Glancy Prongay & Murray LLP

https://rt.newswire.ca/rt.gif?NewsItemId=LA58278&Transmission_Id=202212071300PR_NEWS_USPR_____LA58278&DateId=20221207

comtex tracking

COMTEX_420374922/1005/2022-12-07T13:00:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.